FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,427 | +14.6% | 673,290 | +157.4% | 0.01% | +16.7% |
| Q2 2023 | $1,245 | +225.9% | 261,611 | +590.0% | 0.01% | +140.0% |
| Q4 2022 | $382 | -100.0% | 37,915 | -64.3% | 0.01% | -80.8% |
| Q3 2022 | $2,378,000 | -29.5% | 106,125 | +86.6% | 0.03% | +23.8% |
| Q3 2021 | $3,371,000 | -65.9% | 56,876 | -50.1% | 0.02% | -76.9% |
| Q2 2021 | $9,889,000 | +570.0% | 113,943 | +601.6% | 0.09% | +203.3% |
| Q4 2020 | $1,476,000 | +232.4% | 16,241 | -43.2% | 0.03% | +42.9% |
| Q3 2019 | $444,000 | -23.8% | 28,603 | -20.2% | 0.02% | -76.9% |
| Q3 2018 | $583,000 | – | 35,845 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |